Skip to main content
Atrás
REPL logo

Replimune Group, Inc.

Calidad de datos: 100%
REPL
NASDAQ Healthcare Biotechnology
$6.98
$0.00 (0.00%)
Cap. Mercado: 576.36M
Rango del Día
$6.76 $7.17
Rango de 52 Semanas
$2.68 $13.24
Volumen
1,400,150
Promedio 50D / 200D
$7.61 / $7.71
Cierre Anterior
$6.98

Historial de Precios

Tendencias Financieras

Comparación con Pares

vs mediana del sector Healthcare (626 pares)

Métrica Acción Mediana del Sector
P/E -2.3 0.4
P/B 1.4 2.9
ROE % -62.6 3.8
Net Margin % 3.9
Rev Growth 5Y % 10.0
D/E 0.2 0.2

Precio Objetivo de Analistas

Hold
$13.75 +97.0%
Low: $11.00 High: $18.00
EPS Futuro
-$3.12
Ingresos Est.
1.7 M

Estimaciones de Ganancias

Período EPS Est. Ingresos Est. Analistas
FY2030 $0.80
-$0.06 – $2.25
320 M 2
FY2029 -$0.01
-$0.03 – $0.00
220 M 2
FY2028 -$1.30
-$2.80 – -$0.39
150 M 4

Puntos Clave

Debt/Equity of 0.18 — conservative balance sheet
Negative free cash flow of -198.94M
PEG of 0.61 suggests growth is underpriced

Crecimiento

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Calidad

Return on Equity
-62.58%
ROIC-39.88%
Net MarginN/A
Op. MarginN/A

Seguridad

Debt / Equity
0.18
Current Ratio7.95
Interest Coverage-33.15

Valoración

P/E Ratio
-2.33
P/B Ratio1.39
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 0.0 Net Income (TTM) -247.30M
ROE -62.58% ROA -44.85%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -198.94M
ROIC -39.88% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.18 Current Ratio 7.95
Interest Coverage -33.15 Dividend Yield 0.00%
Valuation
P/E Ratio -2.33 P/B Ratio 1.39
P/S Ratio N/A PEG Ratio 0.61
EV/EBITDA N/A Dividend Yield 0.00%
Market Cap 576.36M Enterprise Value 541.40M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 0.0 0.0 0.0 0.0 0.0
Net Income -247.30M -215.79M -174.28M -118.04M -80.87M
EPS (Diluted) -3.07 -3.24 -2.99 -2.26 -1.75
Gross Profit 0.0 0.0 0.0 -4.58M -4.14M
Operating Income -261.63M -234.77M -177.08M -121.48M -82.76M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 551.33M 487.72M 646.59M 461.19M 543.10M
Total Liabilities 135.49M 113.21M 91.30M 49.96M 44.37M
Shareholders' Equity 415.84M 374.51M 555.29M 411.23M 498.73M
Total Debt 76.17M 75.87M 60.76M 32.84M 33.28M
Cash & Equivalents 111.12M 74.46M 146.59M 105.95M 182.52M
Current Assets 495.88M 433.67M 592.60M 403.98M 483.75M
Current Liabilities 62.36M 40.44M 33.83M 20.76M 14.55M